C4 Therapeutics (CCCC)
C4 Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
42.7M
Short interest
settlement 2026-10-15
16.9
Days to cover
-0.7 days vs prior
44.6%
Short share of volume
2026-11-02
5,501
Fails to deliver
settlement 2026-09-23
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CCCC is 42,722,018 shares, up 2,532,731 shares over the last month. Over the last 48 readings it ranged from 3,521,151 shares (30 September 2025) to 42,722,018 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 2.5M shares a day that is 16.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cccc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 42,722,018 | +5.8% | 2,520,136 | 16.95 |
| 2026-09-30 | 40,395,665 | +0.5% | 2,289,003 | 17.65 |
| 2026-09-15 | 40,189,287 | +7.4% | 1,771,956 | 22.68 |
| 2026-08-31 | 37,413,259 | +9.9% | 2,235,382 | 16.74 |
| 2026-08-14 | 34,048,321 | +11.9% | 2,444,712 | 13.93 |
| 2026-07-31 | 30,427,514 | +27.8% | 2,735,917 | 11.12 |
| 2026-07-15 | 23,815,010 | -4.7% | 3,579,482 | 6.65 |
| 2026-06-30 | 24,997,175 | +12.4% | 4,757,093 | 5.25 |
| 2026-06-15 | 22,246,308 | +2.8% | 2,336,354 | 9.52 |
| 2026-05-29 | 21,650,001 | +1.9% | 2,295,870 | 9.43 |
| 2026-05-15 | 21,254,462 | +0.9% | 3,661,085 | 5.81 |
| 2026-04-30 | 21,055,109 | +0.1% | 1,935,252 | 10.88 |
| 2026-04-15 | 21,042,260 | +30.2% | 4,170,419 | 5.05 |
| 2026-03-31 | 16,157,271 | +19.4% | 1,918,825 | 8.42 |
| 2026-03-13 | 13,534,910 | +58.8% | 3,621,849 | 3.74 |
| 2026-02-27 | 8,520,947 | +19.6% | 2,505,143 | 3.40 |
| 2026-02-13 | 7,121,324 | -1.2% | 869,254 | 8.19 |
| 2026-01-30 | 7,207,214 | -2.3% | 1,878,547 | 3.84 |
| 2026-01-15 | 7,379,826 | +1.4% | 1,274,669 | 5.79 |
| 2025-12-31 | 7,281,152 | +1.5% | 2,079,766 | 3.50 |
| 2025-12-15 | 7,172,653 | +28.4% | 1,637,116 | 4.38 |
| 2025-11-28 | 5,588,028 | +15.3% | 1,154,179 | 4.84 |
| 2025-11-14 | 4,848,155 | +0.8% | 1,658,195 | 2.92 |
| 2025-10-31 | 4,811,669 | +20.7% | 2,541,285 | 1.89 |
| 2025-10-15 | 3,987,152 | +13.2% | 2,703,425 | 1.47 |
| 2025-09-30 | 3,521,151 | -0.6% | 1,893,717 | 1.86 |
| 2025-09-15 | 3,541,042 | -6.4% | 1,647,706 | 2.15 |
| 2025-08-29 | 3,781,945 | -8.8% | 1,148,368 | 3.29 |
| 2025-08-15 | 4,145,430 | -11.0% | 2,014,254 | 2.06 |
| 2025-07-31 | 4,656,847 | +14.4% | 1,273,413 | 3.66 |
| 2025-07-15 | 4,070,759 | -18.0% | 1,857,469 | 2.19 |
| 2025-06-30 | 4,962,321 | -22.2% | 1,575,829 | 3.15 |
| 2025-06-13 | 6,375,598 | +3.4% | 1,114,561 | 5.72 |
| 2025-05-30 | 6,166,325 | -3.0% | 975,460 | 6.32 |
| 2025-05-15 | 6,357,362 | -0.8% | 999,669 | 6.36 |
| 2025-04-30 | 6,406,921 | -17.1% | 1,514,378 | 4.23 |
| 2025-04-15 | 7,728,480 | -0.4% | 1,095,600 | 7.05 |
| 2025-03-31 | 7,761,891 | -5.0% | 803,485 | 9.66 |
| 2025-03-14 | 8,173,895 | -4.4% | 830,598 | 9.84 |
| 2025-02-28 | 8,547,545 | +6.1% | 1,971,727 | 4.34 |
| 2025-02-14 | 8,059,122 | +8.9% | 1,610,422 | 5.00 |
| 2025-01-31 | 7,400,627 | -20.3% | 1,967,037 | 3.76 |
| 2025-01-15 | 9,282,911 | +7.9% | 1,890,486 | 4.91 |
| 2024-12-31 | 8,604,038 | -3.0% | 1,998,600 | 4.31 |
| 2024-12-13 | 8,869,471 | +11.1% | 2,028,177 | 4.37 |
| 2024-11-29 | 7,986,544 | +7.9% | 1,182,308 | 6.76 |
| 2024-11-15 | 7,401,252 | +26.4% | 1,212,959 | 6.10 |
| 2024-10-31 | 5,854,503 | -12.0% | 556,478 | 10.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CCCC volume is 44.6%, down 13.7 points over the last five sessions. Over the last 30 readings it ranged from 22.4% (22 October 2026) to 87.9% (23 October 2026). The latest reading is in line with the 30-session average of 44.9%, on 944K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 421K | 944K | 44.6% | 2,366 |
| 2026-10-30 | 259K | 693K | 37.3% | 466 |
| 2026-10-29 | 666K | 1.1M | 63.0% | 0 |
| 2026-10-28 | 685K | 1.5M | 45.7% | 0 |
| 2026-10-27 | 866K | 2.0M | 43.0% | 0 |
| 2026-10-26 | 855K | 1.5M | 58.3% | 0 |
| 2026-10-23 | 3.0M | 3.4M | 87.9% | 0 |
| 2026-10-22 | 139K | 623K | 22.4% | 0 |
| 2026-10-21 | 343K | 894K | 38.4% | 0 |
| 2026-10-20 | 859K | 1.6M | 53.2% | 0 |
| 2026-10-19 | 475K | 1.0M | 45.6% | 218 |
| 2026-10-16 | 656K | 1.2M | 53.7% | 3,017 |
| 2026-10-15 | 511K | 1.1M | 44.9% | 0 |
| 2026-10-14 | 750K | 1.4M | 51.7% | 18,581 |
| 2026-10-13 | 687K | 1.7M | 40.2% | 7,462 |
| 2026-10-12 | 212K | 448K | 47.3% | 0 |
| 2026-10-09 | 483K | 1.1M | 45.1% | 0 |
| 2026-10-08 | 263K | 509K | 51.7% | 1,095 |
| 2026-10-07 | 200K | 468K | 42.7% | 0 |
| 2026-10-06 | 504K | 1.0M | 49.0% | 85 |
| 2026-10-05 | 224K | 528K | 42.4% | 300 |
| 2026-10-02 | 703K | 1.3M | 52.7% | 16 |
| 2026-10-01 | 206K | 538K | 38.3% | 0 |
| 2026-09-30 | 272K | 789K | 34.5% | 0 |
| 2026-09-29 | 244K | 541K | 45.1% | 0 |
| 2026-09-28 | 440K | 1.5M | 29.5% | 311 |
| 2026-09-25 | 218K | 802K | 27.2% | 0 |
| 2026-09-24 | 315K | 1.1M | 28.0% | 16,482 |
| 2026-09-23 | 1.3M | 2.6M | 49.4% | 27,475 |
| 2026-09-22 | 226K | 647K | 34.9% | 960 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 23 September 2026, the fails-to-deliver balance in CCCC is 5,501 shares, down 27,031 shares over the last settlement date. Over the last 30 readings it ranged from 14 shares (15 June 2026) to 32,532 shares (21 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-23 | 5,501 | $3.31 | $18K |
| 2026-09-21 | 32,532 | $3.39 | $110K |
| 2026-09-09 | 110 | $3.55 | $391 |
| 2026-09-08 | 6,646 | $3.76 | $25K |
| 2026-08-31 | 3,894 | $3.85 | $15K |
| 2026-08-27 | 81 | $4.24 | $343 |
| 2026-08-25 | 26 | $4.10 | $107 |
| 2026-08-11 | 16 | $3.62 | $58 |
| 2026-08-10 | 1,955 | $3.73 | $7K |
| 2026-08-07 | 1,976 | $3.64 | $7K |
| 2026-08-06 | 5,736 | $3.62 | $21K |
| 2026-08-04 | 1,204 | $3.50 | $4K |
| 2026-08-03 | 12,660 | $3.48 | $44K |
| 2026-07-17 | 4,357 | $3.58 | $16K |
| 2026-07-10 | 236 | $4.29 | $1K |
| 2026-06-29 | 54 | $4.26 | $230 |
| 2026-06-18 | 8,176 | $3.92 | $32K |
| 2026-06-15 | 14 | $3.90 | $55 |
| 2026-06-12 | 28,293 | $3.87 | $109K |
| 2026-06-10 | 1,002 | $3.58 | $4K |
| 2026-06-04 | 1,064 | $3.96 | $4K |
| 2026-06-03 | 81 | $4.34 | $352 |
| 2026-05-18 | 890 | $3.56 | $3K |
| 2026-05-04 | 2,900 | $2.92 | $8K |
| 2026-04-20 | 7,449 | $2.92 | $22K |
| 2026-04-13 | 2,201 | $2.54 | $6K |
| 2026-03-12 | 353 | $2.99 | $1K |
| 2026-01-20 | 178 | $2.23 | $397 |
| 2026-01-16 | 2,890 | $2.22 | $6K |
| 2025-12-16 | 23,625 | $2.43 | $57K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CCCC in the last 90 days. The most recent filings are listed below. Latest filing: GROGAN DONNA ROY (Director) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GROGAN DONNA ROY | Director | Grant | 5K | $3.14 | $15K | 79K |
| 2026-10-01 | Anderson Kenneth Carl | Director | Grant | 4K | $3.14 | $11K | 76K |
| 2026-09-18 | Adams Kendra | Chief Financial Officer | Tax withholding | 3K | $3.39 | $9K | 382K |
| 2026-09-18 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 6K | $0.00 | $0 | 385K |
| 2026-07-10 | REYNO LEONARD | Chief Medical Officer | Tax withholding | 7K | $4.06 | $30K | 372K |
| 2026-07-10 | REYNO LEONARD | Chief Medical Officer | Exercise or conversion | 15K | $0.00 | $0 | 380K |
| 2026-07-01 | GROGAN DONNA ROY | Director | Grant | 3K | $4.34 | $14K | 75K |
| 2026-07-01 | Anderson Kenneth Carl | Director | Grant | 3K | $4.34 | $12K | 72K |
| 2026-06-01 | Anderson Kenneth Carl | Director | Exercise or conversion | 1K | $2.11 | $2K | 69K |
| 2026-04-01 | GROGAN DONNA ROY | Director | Grant | 5K | $2.70 | $14K | 72K |
| 2026-04-01 | Anderson Kenneth Carl | Director | Grant | 4K | $2.70 | $11K | 68K |
| 2026-02-15 | Hirsch Andrew | President & CEO | Tax withholding | 9K | $1.89 | $17K | 1.1M |
| 2026-02-15 | Hirsch Andrew | President & CEO | Exercise or conversion | 20K | $0.00 | $0 | 1.1M |
| 2026-02-14 | Mahaney Paige | Chief Scientific Officer | Tax withholding | 2K | $1.89 | $5K | 337K |
| 2026-02-14 | Mahaney Paige | Chief Scientific Officer | Exercise or conversion | 7K | $0.00 | $0 | 339K |
| 2026-02-14 | Schick Kelly | Chief People Officer | Tax withholding | 7K | $1.89 | $14K | 300K |
| 2026-02-14 | Schick Kelly | Chief People Officer | Exercise or conversion | 21K | $0.00 | $0 | 307K |
| 2026-02-14 | Hirsch Andrew | President & CEO | Tax withholding | 39K | $1.89 | $74K | 1.1M |
| 2026-02-14 | Hirsch Andrew | President & CEO | Exercise or conversion | 82K | $0.00 | $0 | 1.1M |
| 2026-02-14 | REYNO LEONARD | Chief Medical Officer | Tax withholding | 17K | $1.89 | $31K | 380K |
| 2026-02-14 | REYNO LEONARD | Chief Medical Officer | Exercise or conversion | 31K | $0.00 | $0 | 396K |
| 2026-02-14 | Mossler Mark | Chief Accounting Officer | Tax withholding | 3K | $1.89 | $6K | 72K |
| 2026-02-14 | Mossler Mark | Chief Accounting Officer | Exercise or conversion | 9K | $0.00 | $0 | 75K |
| 2026-02-14 | Boyle Scott N | Chief Business Officer | Tax withholding | 7K | $1.89 | $14K | 299K |
| 2026-02-14 | Boyle Scott N | Chief Business Officer | Exercise or conversion | 21K | $0.00 | $0 | 306K |
| 2026-02-14 | Adams Kendra | Chief Financial Officer | Tax withholding | 15K | $1.89 | $29K | 385K |
| 2026-02-14 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 31K | $0.00 | $0 | 400K |
| 2026-02-13 | Mahaney Paige | Chief Scientific Officer | Grant | 240K | $0.00 | $0 | 339K |
| 2026-02-13 | Schick Kelly | Chief People Officer | Tax withholding | 2K | $1.89 | $3K | 307K |
| 2026-02-13 | Schick Kelly | Chief People Officer | Exercise or conversion | 5K | $0.00 | $0 | 309K |
| 2026-02-13 | Schick Kelly | Chief People Officer | Grant | 200K | $0.00 | $0 | 309K |
| 2026-02-13 | Hirsch Andrew | President & CEO | Grant | 700K | $0.00 | $0 | 1.1M |
| 2026-02-13 | REYNO LEONARD | Chief Medical Officer | Grant | 240K | $0.00 | $0 | 396K |
| 2026-02-13 | Mossler Mark | Chief Accounting Officer | Grant | 57K | $0.00 | $0 | 75K |
| 2026-02-13 | Boyle Scott N | Chief Business Officer | Tax withholding | 2K | $1.89 | $3K | 306K |
| 2026-02-13 | Boyle Scott N | Chief Business Officer | Exercise or conversion | 5K | $0.00 | $0 | 308K |
| 2026-02-13 | Boyle Scott N | Chief Business Officer | Grant | 200K | $0.00 | $0 | 308K |
| 2026-02-13 | Adams Kendra | Chief Financial Officer | Tax withholding | 2K | $1.89 | $4K | 400K |
| 2026-02-13 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 402K |
| 2026-02-13 | Adams Kendra | Chief Financial Officer | Grant | 240K | $0.00 | $0 | 402K |
| 2026-01-16 | REYNO LEONARD | Chief Medical Officer | Sell | 10K | $2.22 | $22K | 156K |
| 2026-01-02 | GROGAN DONNA ROY | Director | Grant | 8K | $1.93 | $15K | 66K |
| 2026-01-02 | Anderson Kenneth Carl | Director | Grant | 6K | $1.93 | $11K | 147K |
| 2025-10-28 | Mahaney Paige | Chief Scientific Officer | Tax withholding | 6K | $2.58 | $15K | 99K |
| 2025-10-28 | Mahaney Paige | Chief Scientific Officer | Exercise or conversion | 19K | $0.00 | $0 | 105K |
| 2025-10-01 | GROGAN DONNA ROY | Director | Grant | 7K | $2.15 | $14K | 59K |
| 2025-10-01 | Anderson Kenneth Carl | Director | Grant | 5K | $2.15 | $12K | 141K |
| 2025-09-18 | Adams Kendra | Chief Financial Officer | Tax withholding | 3K | $3.32 | $9K | 162K |
| 2025-09-18 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 6K | $0.00 | $0 | 165K |
| 2025-07-10 | REYNO LEONARD | Chief Medical Officer | Exercise or conversion | 15K | $0.00 | $0 | 174K |
| 2025-07-10 | REYNO LEONARD | Chief Medical Officer | Tax withholding | 7K | $1.99 | $15K | 166K |
| 2025-07-01 | GROGAN DONNA ROY | Director | Grant | 10K | $1.51 | $15K | 52K |
| 2025-07-01 | Anderson Kenneth Carl | Director | Grant | 8K | $1.51 | $12K | 135K |
| 2025-04-01 | Anderson Kenneth Carl | Director | Grant | 8K | $1.44 | $11K | 128K |
| 2025-04-01 | GROGAN DONNA ROY | Director | Grant | 10K | $1.44 | $14K | 42K |
| 2025-02-18 | Boyle Scott N | Chief Business Officer | Sell | 669 | $3.15 | $2K | 108K |
| 2025-02-15 | Hirsch Andrew | President & CEO | Tax withholding | 9K | $3.18 | $30K | 423K |
| 2025-02-14 | REYNO LEONARD | Chief Medical Officer | Grant | 87K | $0.00 | $0 | 179K |
| 2025-02-14 | REYNO LEONARD | Chief Medical Officer | Tax withholding | 5K | $3.18 | $16K | 174K |
| 2025-02-14 | Mahaney Paige | Chief Scientific Officer | Grant | 28K | $0.00 | $0 | 105K |
| 2025-02-14 | Adams Kendra | Chief Financial Officer | Grant | 87K | $0.00 | $0 | 170K |
| 2025-02-14 | Adams Kendra | Chief Financial Officer | Tax withholding | 5K | $3.18 | $14K | 165K |
| 2025-02-14 | Schick Kelly | Chief People Officer | Tax withholding | 2K | $3.18 | $8K | 109K |
| 2025-02-14 | Schick Kelly | Chief People Officer | Grant | 57K | $0.00 | $0 | 111K |
| 2025-02-14 | Mossler Mark | Chief Accounting Officer | Tax withholding | 2K | $3.18 | $5K | 18K |
| 2025-02-14 | Boyle Scott N | Chief Business Officer | Tax withholding | 2K | $3.18 | $8K | 108K |
| 2025-02-14 | Boyle Scott N | Chief Business Officer | Sell | 490 | $3.15 | $2K | 111K |
| 2025-02-14 | Boyle Scott N | Chief Business Officer | Grant | 57K | $0.00 | $0 | 111K |
| 2025-02-14 | Siegel Jolie | Chief Legal Officer | Tax withholding | 3K | $3.18 | $9K | 108K |
| 2025-02-14 | Siegel Jolie | Chief Legal Officer | Grant | 57K | $0.00 | $0 | 111K |
| 2025-02-14 | Hirsch Andrew | President & CEO | Tax withholding | 13K | $3.18 | $41K | 433K |
| 2025-02-14 | Hirsch Andrew | President & CEO | Grant | 224K | $0.00 | $0 | 445K |
| 2025-02-13 | Adams Kendra | Chief Financial Officer | Tax withholding | 2K | $3.20 | $6K | 83K |
| 2025-02-13 | Schick Kelly | Chief People Officer | Tax withholding | 2K | $3.20 | $6K | 55K |
| 2025-02-13 | Boyle Scott N | Chief Business Officer | Tax withholding | 2K | $3.20 | $6K | 55K |
| 2025-02-13 | Siegel Jolie | Chief Legal Officer | Tax withholding | 2K | $3.20 | $7K | 54K |
| 2025-01-02 | Anderson Kenneth Carl | Director | Grant | 3K | $3.66 | $11K | 120K |
| 2025-01-02 | GROGAN DONNA ROY | Director | Grant | 4K | $3.66 | $14K | 33K |
| 2024-11-07 | Hirsch Andrew | President & CEO | Exercise or conversion | 13K | price not stated in the filing | not stated | 227K |
| 2024-11-07 | Hirsch Andrew | President & CEO | Tax withholding | 6K | $6.04 | $34K | 222K |
| 2024-11-07 | Siegel Jolie | Chief Legal Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 58K |
| 2024-11-07 | Siegel Jolie | Chief Legal Officer | Tax withholding | 1K | $6.04 | $7K | 56K |
| 2024-11-07 | Schick Kelly | Chief People Officer | Tax withholding | 1K | $6.04 | $7K | 56K |
| 2024-11-07 | Schick Kelly | Chief People Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 58K |
| 2024-11-07 | Adams Kendra | Chief Financial Officer | Tax withholding | 1K | $6.04 | $7K | 84K |
| 2024-11-07 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 86K |
| 2024-11-07 | Boyle Scott N | Chief Business Officer | Exercise or conversion | 4K | price not stated in the filing | not stated | 58K |
| 2024-11-07 | Boyle Scott N | Chief Business Officer | Tax withholding | 1K | $6.04 | $7K | 57K |
| 2024-10-28 | Mahaney Paige | Chief Scientific Officer | Grant | 77K | $0.00 | $0 | 77K |
| 2024-10-01 | Anderson Kenneth Carl | Director | Grant | 2K | $5.56 | $11K | 117K |
| 2024-10-01 | GROGAN DONNA ROY | Director | Grant | 2K | $5.56 | $14K | 29K |
| 2024-09-18 | Adams Kendra | Chief Financial Officer | Tax withholding | 2K | $6.38 | $12K | 82K |
| 2024-09-16 | Siegel Jolie | Chief Legal Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 55K |
| 2024-09-16 | Siegel Jolie | Chief Legal Officer | Tax withholding | 661 | $6.36 | $4K | 54K |
| 2024-09-16 | Schick Kelly | Chief People Officer | Tax withholding | 661 | $6.36 | $4K | 54K |
| 2024-09-16 | Schick Kelly | Chief People Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 55K |
| 2024-09-16 | Fisher Stewart | Chief Scientific Officer | Tax withholding | 661 | $6.36 | $4K | 131K |
| 2024-09-16 | Fisher Stewart | Chief Scientific Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 131K |
| 2024-09-16 | Adams Kendra | Chief Financial Officer | Exercise or conversion | 2K | price not stated in the filing | not stated | 84K |
| 2024-09-16 | Adams Kendra | Chief Financial Officer | Tax withholding | 661 | $6.36 | $4K | 84K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for CCCC worth $2.5M at the prices reported; 4 in the last 90 days worth $2.1M. Latest: Mark Mossler filed on 2026-08-14 to sell 4,139 shares ($18K) from 2026-08-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-14 | Mark MosslerOfficer | 4K | $18K | 0.003% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-14 | JAY GELDMACHERFormer REZI CEO | 83K | $1.9M | 0.109% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-13 | Mark MosslerOfficer | 15K | $61K | 0.012% | 2026-08-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-12 | Mark MosslerOfficer | 20K | $77K | 0.016% | 2026-08-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-28 | Mark MosslerFormer Section 16 Officer | 9K | $35K | 0.008% | 2026-05-27 | E*Trade |
| 2026-03-09 | JOLIE M SIEGELOfficer | 101K | $379K | 0.104% | 2026-03-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON25 holders report 5% or more of CCCC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Lynx1 Capital Management LP at 10.0% of the class (15,423,691 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Squadron Master Fund LPpartnership | 7.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Squadron Capital Management LLCinvestment adviser, parent holding company | 7.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Matthew Sesterhennparent holding company, individual | 7.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | William Blankparent holding company, individual | 7.6M | 6.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Rajeev Shahparent holding company, individual | 11.4M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | RA Capital Healthcare Fund, L.P.partnership | 11.4M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | RA Capital Management, L.P.investment adviser, partnership | 11.4M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Peter Kolchinskyparent holding company, individual | 11.4M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Lynx1 Capital Management LPpartnership | 15.4M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Weston Nicholsindividual | 15.4M | 10.0% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 3 | Morgan Stanleyparent holding company, corporation | 8.9M | 8.0% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 3 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 8.7M | 7.9% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 3 | Morgan Stanley & Co. LLCbroker-dealer, corporation | 134K | 0.1% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 7.7M | 6.9% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Steven A. Cohenindividual | 169K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Capital Advisors, Inc.corporation | 169K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Point72 Asset Management, L.P.partnership | 169K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G | Sirenia Capital Management LPinvestment adviser, partnership | 23.5M | 9.9% | 2026-03-31 |
| 2026-05-15 | 13G | Alex Silversteinparent holding company, individual | 23.5M | 9.9% | 2026-03-31 |
| 2026-04-22 | 13G/Ano. 6 | Wasatch Advisors LPinvestment adviser | 4.6M | 4.7% | 2026-03-31 |
| 2026-02-17 | 13G/Ano. 3 | OrbiMed Capital LLCinvestment adviser | 884K | 1.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 3 | OrbiMed Advisors LLCinvestment adviser | 521K | 0.5% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Guy Levyindividual | 10.3M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Capital Group, LLCother entity | 10.4M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Capital Management, L.P.partnership | 10.3M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus GP, LLCother entity | 10.3M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Capital Master Fund, L.P.non-US institution | 10.4M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Capital, LLCother entity | 10.4M | 10.0% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Private Equity GP III, LLCother entity | 6.1M | 5.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus PE GP III, LLCother entity | 6.1M | 5.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 2 | Soleus Private Equity Fund III, L.P.partnership | 6.1M | 5.9% | 2025-12-31 |
| 2025-10-24 | 13G | BCLS II Equity Opportunities, LPpartnership | 6.1M | 6.3% | 2025-10-17 |
| 2025-10-24 | 13G | Bain Capital Life Sciences Fund II, L.P.partnership | 991K | 1.1% | 2025-10-17 |
| 2025-10-24 | 13G | BCIP Life Sciences Associates, LPpartnership | 121K | 0.1% | 2025-10-17 |
13F holders
Tracked managers holding CCCC at their latest 13F. JSON6 of the 30 tracked managers held CCCC at their latest 13F, $51.3M in total at quarter-end prices. Citadel Advisors is the largest at $19.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 4.2M | $19.6M | 0.00% | +1.7M |
| Two Sigma Investments | 2026-06-30 | 3.5M | $16.2M | 0.01% | +434K |
| D. E. Shaw & Co. | 2026-06-30 | 1.7M | $8.1M | 0.00% | +681K |
| Renaissance Technologies | 2026-06-30 | 1.2M | $5.6M | 0.01% | -1.3M |
| Millennium Management | 2026-06-30 | 215K | $1.0M | 0.00% | -1.2M |
| Point72 Asset Management | 2026-06-30 | 174K | $812K | 0.00% | +5K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
C4 Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows C4 Therapeutics (CCCC), SEC CIK 1662579, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-23.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1662579Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CCCC is sold short?
42,722,018 shares were held short at the 2026-10-15 settlement, 16.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CCCC's daily short volume?
On 2026-11-02, 420,631 of the 943,694 CCCC shares reported to FINRA were sold short, 44.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CCCC have fails to deliver?
The SEC's latest file shows 5,501 CCCC shares failed to deliver at settlement 2026-09-23. Fails are reported per settlement date and published twice a month with a lag.
Are CCCC insiders buying or selling?
No open-market insider trades were reported for CCCC in the last 90 days. The most recent filings are listed below. Latest filing: GROGAN DONNA ROY (Director) on 2026-10-01.
Have CCCC insiders filed to sell?
6 Form 144 notices on file for CCCC worth $2.5M at the prices reported; 4 in the last 90 days worth $2.1M. Latest: Mark Mossler filed on 2026-08-14 to sell 4,139 shares ($18K) from 2026-08-14.
Who owns 5% or more of CCCC?
25 holders report 5% or more of CCCC in their latest filing, all on Schedule 13G (passive). The largest reported stake is Lynx1 Capital Management LP at 10.0% of the class (15,423,691 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own CCCC?
6 of the 30 tracked 13F managers held CCCC shares at their latest filing, $51.3M in all. The largest: Ken Griffin's Citadel Advisors (4.2M shares, $19.6M), Two Sigma Investments (3.5M shares, $16.2M), D. E. Shaw & Co. (1.7M shares, $8.1M), Renaissance Technologies (1.2M shares, $5.6M), Izzy Englander's Millennium Management (215K shares, $1.0M), Steve Cohen's Point72 Asset Management (174K shares, $812K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.